The survival period of chronic granulomas depends on the individual patient, the evolution of the disease and the way the disease is treated, not everyone has a long survival period. The typical survival period is 39-47 months, and even a few patients can continue for 10-20 years.
Survival is based on the overall population of the disease. The individual circumstances of a specific patient can affect the progression of the disease, treatment and prognosis. For example, differences in a patient’s immunologic antigen expression, cytogenetic chromosomal karyotypes, and molecular biology alterations can affect treatment and prognosis, and thus patient survival.
Lentigo is a malignant myeloproliferative neoplasm occurring in multifunctional hematopoietic stem cells. The progression of lentigo generally goes through a chronic phase, an accelerated phase, and an acute phase.
The chronic phase usually lasts 1-4 years, the accelerated phase can last from a few months to several years, and the acute phase is the terminal phase of lentigo, which has a very poor prognosis and often results in death within a few months. Treatment of lentigo should focus on the early chronic phase to avoid transformation of the disease.
Since the application of molecular targeted therapy, imatinib, a first-generation tyrosine kinase inhibitor, the survival of lentigo has been significantly prolonged. The 10-year overall survival rate for patients with lentigo treated with imatinib can reach 84%.
The treatment of lentigo should focus on the early chronic phase to avoid transformation of the disease, and once it enters the accelerated or acute phase, the prognosis is poor. Therefore, if you feel unwell and suspect that you are suffering from lentigo, it is recommended that you consult a doctor in time for early detection and early treatment.
Under the professional guidance of hematologists, we should standardize the treatment, control the progression of the disease, and strive for cytogenetic and molecular biology level of remission.